Dishman Carbogen Amcis Ltd

Dishman Carbogen Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Dishman Carbogen Amcis Ltd

₹ 195 -7.79%
22 May - close price
dishmangroup.com BSE: 540701 NSE: DCAL
About

Dishman Carbogen Amcis Ltd is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as specialty chemicals, vitamins & chemicals and disinfectants with presence in Switzerland, UK, Europe, China and other countries.[1]

Key Points

Business Segments & Revenue Contribution

Website BSE NSE
  • Market Cap ₹ 3,048 Cr.
  • Current Price ₹ 195
  • High / Low ₹ 322 / 128
  • Stock P/E
  • Book Value ₹ 248
  • Dividend Yield 0.00 %
  • ROCE 0.59 %
  • ROE -0.97 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Stock is trading at 0.79 times its book value

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 2.94% over past five years.
  • Company has a low return on equity of -1.03% over last 3 years.
  • Earnings include an other income of Rs.84.5 Cr.
  • Company has high debtors of 269 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE 1000

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
113.13 69.55 59.72 86.82 111.26 103.41 93.29 97.04 106.10 62.86 60.30 39.68 68.72
106.78 74.57 62.64 83.65 99.69 88.51 79.89 74.08 85.57 59.43 55.89 43.18 67.74
Operating Profit 6.35 -5.02 -2.92 3.17 11.57 14.90 13.40 22.96 20.53 3.43 4.41 -3.50 0.98
OPM % 5.61% -7.22% -4.89% 3.65% 10.40% 14.41% 14.36% 23.66% 19.35% 5.46% 7.31% -8.82% 1.43%
14.79 14.44 35.66 13.11 -3.21 11.59 23.93 -8.01 5.47 37.42 11.17 7.10 28.83
Interest 17.03 17.76 17.42 17.14 15.87 15.73 15.59 17.77 21.31 20.26 20.61 23.51 22.14
Depreciation 23.45 24.69 24.58 26.22 26.12 16.32 16.30 16.48 16.10 16.47 15.79 15.16 15.15
Profit before tax -19.34 -33.03 -9.26 -27.08 -33.63 -5.56 5.44 -19.30 -11.41 4.12 -20.82 -35.07 -7.48
Tax % -47.10% -35.42% -37.58% -32.87% -7.46% -37.59% -161.95% -31.19% -35.41% 35.19% -34.68% -34.05% -41.98%
-10.23 -21.33 -5.78 -18.18 -31.12 -3.47 14.25 -13.28 -7.37 2.67 -13.60 -23.13 -4.34
EPS in Rs -0.65 -1.36 -0.37 -1.16 -1.98 -0.22 0.91 -0.85 -0.47 0.17 -0.87 -1.48 -0.28
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
0 7 451 474 549 581 200 307 403 327 400 232
0 5 303 308 356 401 253 267 394 321 328 226
Operating Profit -0 2 148 166 194 179 -53 40 9 7 72 5
OPM % 25% 33% 35% 35% 31% -26% 13% 2% 2% 18% 2%
0 0 71 66 72 64 59 53 49 60 33 85
Interest 1 1 39 35 47 47 34 37 58 68 70 87
Depreciation 0 0 136 134 136 141 141 140 96 102 65 63
Profit before tax -0 1 44 62 82 55 -169 -84 -96 -103 -31 -59
Tax % 0% 12% 45% 40% 31% 31% 38% -63% -39% -26% -68% -35%
-0 1 24 37 56 39 -233 -32 -59 -76 -10 -38
EPS in Rs 2.30 3.47 2.46 -14.85 -2.01 -3.75 -4.87 -0.63 -2.45
Dividend Payout % 0% 0% 0% 0% 6% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 42%
5 Years: 3%
3 Years: -17%
TTM: -42%
Compounded Profit Growth
10 Years: %
5 Years: 13%
3 Years: 10%
TTM: -243%
Stock Price CAGR
10 Years: %
5 Years: 0%
3 Years: 14%
1 Year: -20%
Return on Equity
10 Years: -1%
5 Years: -1%
3 Years: -1%
Last Year: -1%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 0.05 0.05 0.00 32 32 31 31 31 31 31 31 31
Reserves -1 0 4,771 4,759 4,860 4,764 4,643 4,200 4,083 4,021 3,999 3,851
10 9 445 622 584 573 538 535 593 536 686 634
3 3 321 394 339 366 339 448 473 488 405 610
Total Liabilities 12 12 5,537 5,807 5,816 5,735 5,552 5,214 5,181 5,077 5,122 5,126
0 0 1,927 1,853 1,715 1,633 1,510 1,356 1,382 1,416 1,401 1,372
CWIP 0 0 41 48 70 89 121 118 143 74 41 23
Investments 0 0 2,761 2,937 2,907 2,900 2,882 3,032 2,913 2,848 2,841 2,844
12 12 808 969 1,124 1,113 1,039 708 743 739 840 887
Total Assets 12 12 5,537 5,807 5,816 5,735 5,552 5,214 5,181 5,077 5,122 5,126

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
-1 3 270 20 120 197 -2 227 -53 24 56 46
0 0 -16 -175 -24 -74 62 -173 41 97 -80 22
1 -2 -225 142 -85 -124 -71 -46 1 -131 88 -120
Net Cash Flow -0 1 29 -12 10 -2 -10 9 -11 -10 64 -52
Free Cash Flow -1 3 170 -55 78 126 -48 190 -175 -12 2 19
CFO/OP 13,100% 160% 208% 27% 72% 120% -11% 591% -556% 373% 81% 914%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 0 58 108 86 91 217 78 133 205 160 269
Inventory Days 390 397 500 390 690 723 389 534 374 1,440
Days Payable 149 207 210 157 204 198 182 365 201 699
Cash Conversion Cycle 0 298 298 376 324 703 604 340 374 333 1,010
Working Capital Days 467 71 90 95 14 82 -111 -123 -62 -74 -342
ROCE % 21% 3% 2% 2% 2% -2% -1% -1% -1% 1% 1%

Insights

In beta
Mar 2023 Mar 2024 Mar 2025
Global Manufacturing Facilities
Number

Log in to view insights

Please log in to see hidden values.

Login
New Product Development Pipeline
CHF Million
Number of Clients
Number
Number of Late Phase III Molecules
Number
Number of Marketable Molecules Commercialised
Number
R&D Labs and HIPO Labs
Number
Working Capital Cycle
Days
Bavla Site Capacity Utilization
%
Commercial Pipeline (Carbogen Amcis)
CHF Million
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32%
8.90% 8.80% 8.60% 8.70% 8.05% 8.18% 8.75% 9.49% 9.94% 8.07% 7.66% 7.45%
3.13% 3.51% 3.68% 2.36% 1.47% 1.22% 1.42% 1.26% 1.27% 1.37% 1.27% 1.63%
28.65% 28.37% 28.39% 29.63% 31.17% 31.29% 30.51% 29.94% 29.48% 31.23% 31.75% 31.60%
No. of Shareholders 56,22156,27252,33650,65653,68355,28052,82250,75749,74449,45548,48149,009

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls